Background: Neuromyelitis optica (NMO) is a severe inflammatory demyelinating disease of the CNS in which a pathogenic role of anti-aquaporin-4 (AQP4) antibodies has been suggested. Although AQP4 is expressed in human cortex, recent histologic studies have failed to find any evidence of cortical demyelination in NMO.
Neuromyelitis optica (NMO) is considered an autoimmune-mediated demyelinating disease of the CNS, clinically characterized by the recurrence of episodes of optic neuritis and inflammatory myelitis. 1, 2 Despite the existence of international criteria, 3 the diagnosis of NMO can be troublesome, especially at clinical onset, and its differentiation from multiple sclerosis (MS) might not be straightforward. Indeed, some patients with NMO may have the transient appearance of immunoglobulin G oligoclonal bands in the CSF, 4, 5 others may present with brainstem or periventricular or atypical white matter (WM) lesions, 3, [5] [6] [7] others may have spinal cord lesions that do not perfectly respect the neuroimaging criteria. 8, 9 Antibodies against the water channel aquaporin-4 (AQP4) have been claimed to play a pathogenic role in NMO and may be used to achieve an early diagnosis. 10 -12 However, not all patients with NMO are positive for anti-AQP4 antibodies, 13, 14 while a small percentage of patients with MS having optic neuritis or myelitis may be anti-AQP4-positive. 10, 15 Thus, the identification of other peculiar features that may differentiate NMO from other inflammatory diseases of the CNS may further contribute to an early and correct diagnosis, with relevant therapeutic rebounds.
The demonstration of AQP4 in human brain cortex 16 suggests the inevitable involvement of the cortical gray matter (GM) in NMO pathology. However, when the occult damage of normal-appearing GM in NMO was evaluated by non-conventional MRI, conflicting results were obtained. [17] [18] [19] [20] Moreover, a recent histopathologic study on 19 autopsied patients failed to disclose evidence of cortical demyelination in NMO. 21 Inasmuch as cortical pathology is a relevant aspect of MS 22, 23 and may be observed in a high percentage of patients with MS even at clinical onset, 24 -27 we studied the cortex of patients with NMO in order to identify possible changes that could be used in vivo for diagnostic or prognostic purposes.
METHODS Patients and controls. Twenty-one Italian
(from the Multiple Sclerosis Centre of the Veneto Region, University Hospital of Padova) and 9 Korean (from the Department of Neurology, Hallym University, Seoul) patients with a diagnosis of NMO achieved in agreement with the established international criteria 3 were included in this cross-sectional study. Thirty Italian patients with relapsing-remitting MS (RRMS) and 30 Italian normal controls (NC), age-and gender-matched with the patients with NMO, were included in the study. Patients with NMO and patients with RRMS were also matched for disease duration and Expanded Disability Status Scale (EDSS). NMO antibodies were tested in all patients with NMO and were positive in 25 patients. At the time of the study, 21 patients with NMO were taking immunosuppressive drug, 7 were on IV immunoglobulin treatment, and 2 were therapy-free. Nine patients with NMO had been treated with immunosuppressive drugs before study entry. All patients with RRMS were taking interferon-␤ treatment. The demographic and clinical characteristics of patients with NMO and patients with RRMS and NC are summarized in table 1. The respective local ethics committees approved the study and informed consent was obtained from all patients.
Image acquisition.
In Padova and Seoul, the patients were studied with the same standardized MRI protocol (figure 1, A and B). All images were acquired using a 1.5 T scanner (Achieva, Philips Medical Systems, Best, the Netherlands) with 33 mT/m power gradient, and a 16-channel head coil. The following images were acquired from each subject: 1) double inversion recovery (DIR): repetition time (TR) ϭ 15,631 msec, echo time (TE) ϭ 25 msec, inversion time (TI) ϭ 3,400 msec, delay (second TI) ϭ 325 msec, echo train length (ETL) ϭ 17, 70 contiguous axial slices with a thickness ϭ 2.0 mm, a matrix size ϭ 130 ϫ 256, and a field of view (FOV) ϭ 250 ϫ 200 mm 2 ; 2) fluid-attenuated inversion recovery (FLAIR): TR ϭ 10,000 msec, TE ϭ 120 msec, TI ϭ 2,500 msec, ETL ϭ 23, 50 contiguous axial slices with a thickness ϭ 3.0 mm, a matrix size ϭ 172 ϫ 288, and an FOV ϭ 250 ϫ 200 mm 2 ; 3) 3 volumetric fast field echo T1-weighted images: 120 contiguous axial slices with the off-center positioned on zero, TR ϭ 25 msec, TE ϭ 4.6 msec, flip angle ϭ 30°, slice thickness ϭ 1.2 mm, matrix size ϭ 256 ϫ 256, and an FOV ϭ 250 ϫ 250 mm 2 .
Image analysis. White matter and gray matter lesions. All
images were analyzed at the Advanced Neuroimaging Laboratory of the Multiple Sclerosis Centre in Padova, by consensus of 2 experienced observers and in a blind fashion. The number of cortical lesions (CLs) was assessed on DIR images (figure 1, A and B, and figure 2, A and B) following the recent recommendations for CL scoring in patients with MS. 27 The number of WM lesions was assessed on FLAIR images.
Cortical thickness. Measurements of global and regional cortical thickness (CTh) and deep GM atrophy were performed using the semiautomatic software (i.e., FreeSurfer, available at Cortical thickness in patients with NMO and NC. No difference in the global CTh was found between patients with NMO and NC ( p ϭ 0.105), but a mild thinning was observed in the postcentral ( p ϭ 0.018), precentral ( p ϭ 0.009), and calcarine ( p ϭ 0.015) gyri ( figure 2E ) and a decreased volume of thalamus ( p ϭ 0.036) in patients with NMO (table  2) . The CTh volume of these 4 regions correlated significantly with disease duration (r values ranged between 0.42 and 0.50, p values ranged between 0.05 and 0.01) while only the CTh of precentral gyrus slightly correlated with the motor function system of EDSS (r ϭ 0.42, p ϭ 0.028). RRMS had a significant reduction of global CTh ( p Ͻ 0.001), a significant thinning of several frontal, temporal, and parietal gyri (figure 2F), and a decreased volume of the basal ganglia compared to both NC and patients with NMO ( p ranging between 0.05 and 0.001). DISCUSSION We found that the cortex of patients with NMO, with high disease duration and moderate disability, was free from DIR-detectable CLs and showed only a mild decrease in the thickness of some cortical areas. These findings confirm recently published histologic 21 and MRI 19, 30 observations that seem to exclude a relevant involvement of the cortex in the immune-mediated pathologic process that underlies NMO. Thus, the presence of a relatively mild cortical pathology distinguishes NMO from MS, where the accumulation of focal intracortical lesions and widespread cortical atrophy constitute major pathologic features. 31, 32 Indeed, the majority of patients with RRMS having similar disease duration had DIR-detectable CL evidence of a global cortical thinning.
Since NMO is associated with the presence of anti-AQP4 antibodies, a water channel antigen expressed in the astrocytic foot processes, 10,33 the lack of focal cortical pathology in this disease is particularly worthy of interest. Indeed, while demyelinating lesions have been described in AQP4-enriched periventricular WM, a recent detailed immunohistochemical analysis of 19 brains showed the absence of cortical demyelination in NMO, 21 despite the welldocumented presence of AQP4 in the cortex. 6, 16, 34 From a pathologic point of view, it has been suggested that both the local tissue structure (bloodbrain barrier permeability, astrocytic organization, microglia network) 35, 36 and the differential expression of M1 and M2 isoforms of AQP4 37,38 may play a role in inhibiting or modulating the NMOassociated immune-mediated pathology. From a clinical point of view, the absence of cortical demyelination, which is extensive in chronic MS, where it affects up to 70% of the cortex, 39 might explain why NMO usually does not evolve in a secondary progressive phase, which in MS seems strongly related to cortical pathology. 25, 32 Thus, understanding why the cortex is almost completely spared in NMO despite cortical expression of AQP4 is a challenging question for understanding the disease pathogenesis and its difference from MS. The selective mild atrophy observed in the primary motor and sensory cortex and in the thalamus of NMO suggests that the severe spinal cord damage occurring in this disease, in the absence of other WM and GM lesions, induces a retrograde axonal degeneration as recently observed in patients with traumatic spinal cord injury. 40 The atrophy in the primary visual cortex may find a similar explanation. Conversely, this observation is also worthy of interest since it minimizes the role of axonal retrograde degeneration in determining the widespread cortical 26, 31 and cerebellar GM atrophy frequently observed in RRMS.
Our study is based on few patients. Notwithstanding this, the difference in cortical lesions and atrophy between NMO and MS is striking, and we believe that this difference will remain even when increasing the number of the patients. In selective, ambiguous cases, the demonstration of cortical lesions or widespread cortical atrophy may therefore help in the differential diagnosis between NMO and MS. 
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